These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19571107)

  • 1. Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses.
    Garrison KE; Champiat S; York VA; Agrawal AT; Kallas EG; Martin JN; Hecht FM; Deeks SG; Nixon DF
    Clin Vaccine Immunol; 2009 Sep; 16(9):1369-71. PubMed ID: 19571107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals.
    Addo MM; Altfeld M; Rosenberg ES; Eldridge RL; Philips MN; Habeeb K; Khatri A; Brander C; Robbins GK; Mazzara GP; Goulder PJ; Walker BD;
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1781-6. PubMed ID: 11172028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes.
    Hinkula J; Svanholm C; Schwartz S; Lundholm P; Brytting M; Engström G; Benthin R; Glaser H; Sutter G; Kohleisen B; Erfle V; Okuda K; Wigzell H; Wahren B
    J Virol; 1997 Jul; 71(7):5528-39. PubMed ID: 9188627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption.
    de Goede AL; van Deutekom HW; Vrancken B; Schutten M; Allard SD; van Baalen CA; Osterhaus AD; Thielemans K; Aerts JL; Keşmir C; Lemey P; Gruters RA
    AIDS; 2013 Nov; 27(17):2679-89. PubMed ID: 24149085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Specific immune responses to human immunodeficiency virus type 1 Gag, Tat, Rev and Nef proteins].
    Zhai S; Kang WZ; Yu X; Wang SY; Walker BD; Altfeld M; Sun YT
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):175-9. PubMed ID: 15766402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains.
    Tähtinen M; Ranki A; Valle SL; Ovod V; Krohn K
    Biomed Pharmacother; 1997; 51(10):480-7. PubMed ID: 9863510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence evolution and escape from specific immune pressure of an HIV-1 Rev epitope with extensive sequence similarity to human nucleolar protein 6.
    Allard SD; de Goede AL; De Keersmaecker B; Heirman C; Lacor P; Osterhaus AD; Demanet C; Thielemans K; Gruters RA; Aerts JL
    Tissue Antigens; 2012 Mar; 79(3):174-85. PubMed ID: 22309258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.
    Fischer W; Perkins S; Theiler J; Bhattacharya T; Yusim K; Funkhouser R; Kuiken C; Haynes B; Letvin NL; Walker BD; Hahn BH; Korber BT
    Nat Med; 2007 Jan; 13(1):100-6. PubMed ID: 17187074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins.
    Ulich C; Harrich D; Estes P; Gaynor RB
    J Virol; 1996 Jul; 70(7):4871-6. PubMed ID: 8676525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev.
    Gorry PR; Howard JL; Churchill MJ; Anderson JL; Cunningham A; Adrian D; McPhee DA; Purcell DF
    J Virol; 1999 Jan; 73(1):352-61. PubMed ID: 9847339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular insights into human immunodeficiency virus type 1 pathogenesis.
    Feinberg MB; Greene WC
    Curr Opin Immunol; 1992 Aug; 4(4):466-74. PubMed ID: 1356348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes.
    Corbet S; Nielsen HV; Vinner L; Lauemoller S; Therrien D; Tang S; Kronborg G; Mathiesen L; Chaplin P; Brunak S; Buus S; Fomsgaard A
    J Gen Virol; 2003 Sep; 84(Pt 9):2409-2421. PubMed ID: 12917462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.
    Horton H; Havenar-Daughton C; Lee D; Moore E; Cao J; McNevin J; Andrus T; Zhu H; Rubin A; Zhu T; Celum C; McElrath MJ
    J Virol; 2006 Oct; 80(19):9779-88. PubMed ID: 16973582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
    Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
    Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef.
    Allard SD; Pletinckx K; Breckpot K; Heirman C; Bonehill A; Michiels A; van Baalen CA; Gruters RA; Osterhaus AD; Lacor P; Thielemans K; Aerts JL
    Vaccine; 2008 Jul; 26(29-30):3735-41. PubMed ID: 18539368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.
    Liem SE; Ramezani A; Li X; Joshi S
    Hum Gene Ther; 1993 Oct; 4(5):625-34. PubMed ID: 8280800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mathematical model of the Tat-Rev regulation of HIV-1 replication in an activated cell predicts the existence of oscillatory dynamics in the synthesis of viral components.
    Likhoshvai VA; Khlebodarova TM; Bazhan SI; Gainova IA; Chereshnev VA; Bocharov GA
    BMC Genomics; 2014; 15 Suppl 12(Suppl 12):S1. PubMed ID: 25564443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.